MX368577B - Compuestos quimicos. - Google Patents

Compuestos quimicos.

Info

Publication number
MX368577B
MX368577B MX2016011681A MX2016011681A MX368577B MX 368577 B MX368577 B MX 368577B MX 2016011681 A MX2016011681 A MX 2016011681A MX 2016011681 A MX2016011681 A MX 2016011681A MX 368577 B MX368577 B MX 368577B
Authority
MX
Mexico
Prior art keywords
compound
chemical compounds
copd
asthma
preparing
Prior art date
Application number
MX2016011681A
Other languages
English (en)
Other versions
MX2016011681A (es
Inventor
Connolly Stephen
Elisabeth Berglund Susanne
Hemmerling Martin
Kristoffersson Anna
Rune Michael Lundkvist Johan
Hossain Nafizal
Nikitidis Grigorios
Elisabeth Ripa Lena
Shamovsky Igor
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2016011681A publication Critical patent/MX2016011681A/es
Publication of MX368577B publication Critical patent/MX368577B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de una fórmula (I) (ver Fórmula) o una sal farmacéuticamente aceptable de este; un proceso para preparar tal compuesto; y el uso de tal compuesto en el tratamiento de un estado de enfermedad mediado por ENaC (tal como asma, CF o COPD).
MX2016011681A 2014-03-18 2015-03-17 Compuestos quimicos. MX368577B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461954674P 2014-03-18 2014-03-18
PCT/GB2015/050765 WO2015140527A1 (en) 2014-03-18 2015-03-17 Chemical compounds

Publications (2)

Publication Number Publication Date
MX2016011681A MX2016011681A (es) 2016-10-28
MX368577B true MX368577B (es) 2019-10-08

Family

ID=52780553

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011681A MX368577B (es) 2014-03-18 2015-03-17 Compuestos quimicos.

Country Status (38)

Country Link
US (3) US9873678B2 (es)
EP (1) EP3119752B1 (es)
JP (1) JP6502469B2 (es)
KR (1) KR102296041B1 (es)
CN (1) CN106103423B (es)
AP (1) AP2016009447A0 (es)
AR (1) AR099790A1 (es)
AU (1) AU2015233195B2 (es)
CA (1) CA2941807C (es)
CL (1) CL2016002303A1 (es)
CR (1) CR20160479A (es)
CY (1) CY1120509T1 (es)
DK (1) DK3119752T3 (es)
DO (1) DOP2016000232A (es)
EA (1) EA029952B1 (es)
ES (1) ES2679618T3 (es)
GT (1) GT201600190A (es)
HR (1) HRP20181123T1 (es)
HU (1) HUE039425T2 (es)
IL (1) IL247610B (es)
LT (1) LT3119752T (es)
ME (1) ME03056B (es)
MX (1) MX368577B (es)
NI (1) NI201600134A (es)
NZ (1) NZ724063A (es)
PE (1) PE20170205A1 (es)
PH (1) PH12016501808A1 (es)
PL (1) PL3119752T3 (es)
PT (1) PT3119752T (es)
RS (1) RS57487B1 (es)
SG (1) SG11201607751SA (es)
SI (1) SI3119752T1 (es)
SV (1) SV2016005278A (es)
TR (1) TR201810207T4 (es)
TW (1) TWI687410B (es)
UY (1) UY36034A (es)
WO (1) WO2015140527A1 (es)
ZA (1) ZA201607136B (es)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577418A (en) 1969-02-12 1971-05-04 Merck & Co Inc Pyrazinamide derivatives and processes for their preparation
US3573306A (en) 1969-03-05 1971-03-30 Merck & Co Inc Process for preparation of n-substituted 3,5-diamino-6-halopyrazinamides
FI820266L (fi) 1981-02-02 1982-08-03 Ici Plc Alkanolaminderivater
US4550111A (en) 1982-01-29 1985-10-29 Imperial Chemical Industries Plc Alkanolamine derivatives
GB8810933D0 (en) 1987-05-26 1988-06-15 Ici America Inc Heterocyclic compounds
GB8810934D0 (en) 1987-05-26 1988-06-15 Ici America Inc Amides
US4803206A (en) 1988-03-07 1989-02-07 Schering Corporation Antihypertensive acylpyrazines
GB8812342D0 (en) 1988-05-25 1988-06-29 Ici America Inc Bicyclic compounds
GB8812343D0 (en) 1988-05-25 1988-06-29 Ici America Inc Amino compounds
YU41399A (sh) 1997-02-26 2001-09-28 Pfizer Inc. Derivati amida heteroaril-kapronske kiseline, njihovo dobijanje i njihova upotreba kao selektivnih inhibitora mip-1.alfa vezivanjem za njegov ccr1 receptor
GB9930557D0 (en) 1999-12-23 2000-02-16 Rolic Ag Optically active materials
CA2408408C (en) 2000-05-12 2013-07-09 Genzyme Corporation Modulators of tnf- alpha signaling
EA200400648A1 (ru) 2001-11-08 2005-04-28 Элан Фармасьютикалз, Инк. N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20040087571A1 (en) 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
MXPA05006679A (es) 2002-12-20 2005-08-16 Pfizer Prod Inc Inhibidores de la proteina de transferencia de trigliceridos microsomales.
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
EP1812378A2 (en) 2004-10-13 2007-08-01 University of Connecticut Cannabinergic lipid ligands
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
WO2009074575A2 (en) 2007-12-10 2009-06-18 Novartis Ag Organic compounds
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2723938A1 (en) 2008-05-13 2009-11-19 Novartis Ag 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
JP2011522860A (ja) * 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US9505735B2 (en) 2012-06-21 2016-11-29 Whitehead Institute For Biomedical Research Compounds for treating infectious diseases
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9593084B2 (en) 2012-12-17 2017-03-14 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
WO2014099673A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds

Also Published As

Publication number Publication date
AP2016009447A0 (en) 2016-09-30
AR099790A1 (es) 2016-08-17
NI201600134A (es) 2017-03-13
ME03056B (me) 2018-10-20
EP3119752A1 (en) 2017-01-25
EP3119752B1 (en) 2018-05-16
SV2016005278A (es) 2016-11-30
AU2015233195B2 (en) 2017-04-20
AU2015233195A1 (en) 2016-09-22
DK3119752T3 (en) 2018-07-30
UY36034A (es) 2015-09-30
HRP20181123T1 (hr) 2018-09-21
CR20160479A (es) 2017-02-24
DOP2016000232A (es) 2016-10-16
SG11201607751SA (en) 2016-10-28
US10336725B2 (en) 2019-07-02
PH12016501808B1 (en) 2017-01-09
US9873678B2 (en) 2018-01-23
NZ724063A (en) 2018-02-23
SI3119752T1 (en) 2018-08-31
ZA201607136B (en) 2018-04-25
US20180162838A1 (en) 2018-06-14
PL3119752T3 (pl) 2018-09-28
RS57487B1 (sr) 2018-10-31
TWI687410B (zh) 2020-03-11
JP6502469B2 (ja) 2019-04-17
CN106103423A (zh) 2016-11-09
US10954211B2 (en) 2021-03-23
MX2016011681A (es) 2016-10-28
KR20160127135A (ko) 2016-11-02
PE20170205A1 (es) 2017-04-06
KR102296041B1 (ko) 2021-08-30
PH12016501808A1 (en) 2017-01-09
US20190330187A1 (en) 2019-10-31
JP2017512830A (ja) 2017-05-25
EA201691641A1 (ru) 2017-02-28
IL247610A0 (en) 2016-11-30
CN106103423B (zh) 2019-12-06
CA2941807C (en) 2023-03-07
LT3119752T (lt) 2018-08-10
EA029952B1 (ru) 2018-06-29
HUE039425T2 (hu) 2018-12-28
CY1120509T1 (el) 2019-07-10
CL2016002303A1 (es) 2017-01-13
PT3119752T (pt) 2018-07-24
TW201620880A (zh) 2016-06-16
CA2941807A1 (en) 2015-09-24
IL247610B (en) 2019-05-30
TR201810207T4 (tr) 2018-08-27
ES2679618T3 (es) 2018-08-29
US20170107195A1 (en) 2017-04-20
GT201600190A (es) 2019-07-29
WO2015140527A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
GEP20186921B (en) Pyrazolopyridines and pyrazolopyrimidines
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
MX2017015211A (es) Compuestos de naftiridina como inhibidores de quinasa jak.
TW201613864A (en) Novel compounds
PH12018501237A1 (en) Isoindole compounds
PH12017500089B1 (en) Aldosterone synthase inhibitors
PH12014501712A1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
MX2017003294A (es) Quinolinas carboxamidas para usarse en el tratamiento de mielomas multiples.
MX2016010272A (es) Derivado de indolona sustituido por pirrol, metodo de preparacion del mismo, composicion que comprende el mismo y uso del mismo.
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
MD4780B1 (ro) Urei asimetrice p-substituite şi utilizările medicale ale acestora
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
PH12016501808A1 (en) Chemical compounds
MX2017015984A (es) Metodos de usar fluorociclopentenilcitosina.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
MX2016010549A (es) Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas.
TN2014000307A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors

Legal Events

Date Code Title Description
FG Grant or registration